Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Song Qu

Showing results (171-180 of 179) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 179 results.
Cancer Treatment Reviews|November 18, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinomaLiqiong Xue, Tingting Xu, Guochun Cao, et al.
Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
Nature Medicine|March 14, 2025
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trialYuxiang Ma, Yunpeng Yang, Yan Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trialCheng Xu, Si-Yang Wang, Man Nie, et al.
Journal of Hematology & Oncology|May 9, 2023
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumorsYuanyuan Zhao, Yuxiang Ma, Aimin Zang, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Nature Medicine|June 28, 2024
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trialYuankai Shi, Wei Guo, Wei Wang, et al.
Signal Transduction and Targeted Therapy|April 7, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 studyShuang Huang, Feng Liu, Song Qu, et al.
Pageof 18

Showing results (171-180 of 179) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 179 results.
Cancer Treatment Reviews|November 18, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinomaLiqiong Xue, Tingting Xu, Guochun Cao, et al.
Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.
The Lancet. Oncology|June 26, 2021
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialYunpeng Yang, Song Qu, Jingao Li, et al.
Nature Medicine|March 14, 2025
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trialYuxiang Ma, Yunpeng Yang, Yan Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trialCheng Xu, Si-Yang Wang, Man Nie, et al.
Journal of Hematology & Oncology|May 9, 2023
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumorsYuanyuan Zhao, Yuxiang Ma, Aimin Zang, et al.
JAMA Oncology|January 29, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical TrialYan Huang, Dongchen Sun, Huaqiang Zhou, et al.
Nature Medicine|June 28, 2024
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trialYuankai Shi, Wei Guo, Wei Wang, et al.
Signal Transduction and Targeted Therapy|April 7, 2026
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 studyShuang Huang, Feng Liu, Song Qu, et al.
Pageof 18